Skip to main content
Vivesto logo

Vivesto — Investor Relations & Filings

Ticker · VIVE ISIN · SE0000722365 LEI · 5493003TZPR4B7QO9L49 ST Manufacturing
Open in API
Filings indexed 1,069 across all filing types
Latest filing 2020-08-19 Annual Report
Country SE Sweden
Listing ST VIVE

About Vivesto

https://www.vivesto.com/en/

Vivesto is a specialty pharmaceutical company focused on drug development in oncology. The company aims to provide new therapeutic options for patients suffering from hard-to-treat cancers where significant medical needs exist. Its research and development efforts are centered on creating innovative treatments and enhancing the intravenous delivery of established and novel drugs. The company's lead product is Apealea, a formulation of the cancer drug paclitaxel.

Recent filings

Filing Released Lang Actions
Annual Report 2020
Annual Report Classification · 100% confidence The document is titled 'Annual Report 2019/20' and contains comprehensive sections including 'Administration Report', 'Consolidated accounts', 'Parent Company financial statements', 'Notes', and 'Auditor's report'. It covers the full fiscal year from May 1, 2019, to April 30, 2020, and provides detailed financial performance data, management commentary, and strategic outlook. It meets all criteria for an Annual Report. FY 2020
2020-08-19 English
Kallelse till årsstämma i Oasmia Pharmaceutical AB
AGM Information Classification · 98% confidence The document is titled "Kallelse till årsstämma i Oasmia Pharmaceutical AB" (Notice of Annual General Meeting in Oasmia Pharmaceutical AB). It details the date, time, location, registration procedures, voting procedures (including proxy and postal voting), and the proposed agenda for the meeting. The agenda items cover standard AGM topics like election of the chairman, approval of financial statements, remuneration policies, and election of the board and auditor. This content is characteristic of a formal notice and materials related to an Annual General Meeting (AGM). The closest matching category is AGM Information (AGM-R). Although it contains proposals that might be voted on (which could relate to DEF 14A or DVA), the primary purpose and structure of the document is the official call and information package for the AGM itself.
2020-08-10 Swedish
Notice of Annual General Meeting in Oasmia Pharmaceutical AB
AGM Information Classification · 99% confidence The document is explicitly titled "Notice of Annual General Meeting in Oasmia Pharmaceutical AB" and details the date, time, location, registration procedures, and the full proposed agenda for the meeting. The agenda items (e.g., Election of Chairman, Resolution on Board fees, Election of auditor) are characteristic of an AGM notice. Although it mentions the Annual Report and Audit Report under item 8 of the agenda, the document itself is the formal notice convening the meeting, which aligns best with the AGM Information category (AGM-R). It is not the full 10-K, nor is it a general earnings release (ER) or a proxy statement (PSI), but specifically the notice for the Annual General Meeting.
2020-08-10 English
Oasmia’s partner Elevar Therapeutics and Tanner Pharma Announce Global Named Patient Program to Provide Access to Apealea®
Regulatory Filings Classification · 100% confidence The document announces a partnership between Oasmia's partner Elevar Therapeutics and Tanner Pharma to establish a Global Named Patient Program for the drug Apealea®. It details the purpose, scope, and involved parties. Crucially, the end of the document contains an 'Attachments' section listing a PDF file with the title matching the announcement and a timestamp indicating when the information was submitted for publication, suggesting this text is the body of a regulatory announcement or press release about a business development, rather than a core financial report (like 10-K, IR, or ER). Since it is a specific business development announcement (partnership/access program) that doesn't fit perfectly into the main financial/governance categories, and it is not a general regulatory filing fallback (RNS), I must check the specific definitions. This is a business/commercial arrangement announcement. None of the codes (AGM-R, 10-K, AR, MANG, CT, CAP, DVA, DLST, DIRS, ER, SR, XLSX, FS, CGR, IRAT, IR, IP, LTR, TAR, MRQ, MDA, NAV, DIV, PSI, DEF 14A) fit this specific type of partnership announcement well. However, the document structure strongly resembles a press release announcing a significant operational/commercial agreement. Given the options, this type of announcement often falls under general Regulatory Filings (RNS) if a more specific code isn't available, or potentially Capital/Financing Update (CAP) if it involved funding, which it doesn't explicitly. Since it is a formal announcement of a commercial agreement and access program, and it is not a report itself (Rule 2 applies, but this is the announcement text, not just a link), RNS (Regulatory Filings - general fallback) is the most appropriate category for a non-standard business update that is being formally disclosed.
2020-07-27 English
Oasmias partner Elevar Therapeutics och Tanner Pharma startar ett globalt Named Patient Program för att göra Apealea® tillgängligt för patienter
Legal Proceedings Report Classification · 99% confidence The document is a press release dated July 27, 2020, announcing a collaboration between Oasmia Pharmaceutical AB's partner (Elevar Therapeutics) and Tanner Pharma Group to start a global Named Patient Program for the drug Apealea®. This announcement details a strategic business development and access initiative, rather than a formal financial report (like 10-K or IR), a management change (MANG), or a dividend notice (DIV). It is a specific corporate action announcement. Since it is not a standard regulatory filing like 10-K, DEF 14A, or a specific financial report, and it announces a business arrangement, it fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate announcement, or potentially 'Capital/Financing Update' (CAP) if the program implied a significant financial structure change, but 'RNS' is the most appropriate fallback for non-standard press releases detailing operational agreements. Given the content is a press release about a partnership to provide drug access, RNS (Regulatory Filings/General Announcement) is the most suitable classification.
2020-07-27 Swedish
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The document is a navigation page for the Swedish Financial Supervisory Authority (Finansinspektionen) portal for stock market information. It contains links for searching, reporting, and flagging, but does not contain any specific financial data, corporate reports, or regulatory announcements. As it is a general portal interface and does not fit into any specific category, it is classified as a general regulatory filing.
2020-06-18 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.